

MANUAL FOR THE DEVELOPMENT AND ASSESSMENT OF NATIONAL VIRAL HEPATITIS PLANS

A PROVISIONAL DOCUMENT, SEPTEMBER 2015

MANUAL FOR THE DEVELOPMENT AND ASSESSMENT OF NATIONAL VIRAL HEPATITIS PLANS

A PROVISIONAL DOCUMENT, SEPTEMBER 2015

WHO Library Cataloguing-in-Publication Data

Manual for the development and assessment of national viral hepatitis plans: a provisional document.

1.Hepatitis, Viral, Human. 2.National Health Programs. 3.Public Health Surveillance. 4.Handbooks. I.World Health Organization.

ISBN 978 92 4 150935 0

(NLM classification: WC 536)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Glasgow, Scotland

Design and layout: blossoming.it

TABLE OF CONTENTS

| | |
|--|------------|
| Acknowledgements | v |
| Abbreviations and acronyms | vi |
| Preface | vii |
| 1. Introduction | 1 |
| 1.1 Background | 1 |
| 1.2 The importance of planning | 2 |
| 1.3 Aim and objectives | 3 |
| 1.4 Target audience | 3 |
| 1.5 Structure of the manual | 4 |
| 1.6 How to use the manual, topic guide and template | 5 |
| 2. Guiding principles for effective development of a national hepatitis plan | 6 |
| 2.1 Leadership and governance | 6 |
| 2.2 Human rights and equity | 7 |
| 2.3 Health systems strengthening and integration | 7 |
| 2.4 Evidence-informed policy and planning | 8 |
| 2.5 Feasibility, cost-effectiveness and impact | 9 |
| 2.6 A public health approach | 9 |
| 3. National planning for hepatitis within the universal health coverage framework | 10 |
| 4. Process and steps for developing a national hepatitis plan | 11 |
| 4.1 Step 1: Preparation | 12 |
| 4.2 Step 2: Plan development | 14 |
| 4.3 Step 3: Implementation | 16 |
| 4.4 Step 4: Monitoring and evaluation | 17 |
| 5. Contents of a national hepatitis plan | 19 |
| 5.1 Health information systems | 19 |
| 5.2 Providing essential services | 19 |
| 5.3 Covering populations and achieving equity | 27 |
| 5.4 Covering costs | 28 |

| | |
|---|-----------|
| 6. Template for a national hepatitis plan | 29 |
| 6.1 Situational analysis, stakeholder mapping and priority setting | 29 |
| 6.2 Governance and organizational structure | 29 |
| 6.3 Relationship to other policies, strategies, plans and programmes | 29 |
| 6.4 Viral hepatitis response | 30 |
| 6.5 Integration and implementation | 30 |
| 6.6 Financial framework | 30 |
| 7. Monitoring and evaluation framework | 34 |
| 7.1 Monitoring | 35 |
| 7.2 Evaluation | 36 |
| Annex 1. Definition of terms | 37 |
| Annex 2. Process for review and update of a national plan and the associated programme | 39 |
| Annex 3. Planning tools | 40 |
| Annex 4. Topic guide for the assessment of a national programme | 41 |
| Annex 5. Checklist for initiating or scaling up hepatitis treatment services | 47 |
| References | 49 |

ACKNOWLEDGEMENTS

This document went through many iterations and field tests before being published. We sincerely thank all those who provided feedback on the different versions after having used it for programme assessments. Many professionals from a range of backgrounds and specialties have contributed to the writing of this document. WHO is sincerely grateful for their time and support.

Benedetta Allegranzi, World Health Organization; Rana Jawad Asghar, Field Epidemiology and Training Program, Islamabad, Pakistan; Francisco Averhoff, US Centers for Disease Control and Prevention, Atlanta, USA; Mazuwa Banda, World Health Organization; Isabelle Bergeri, World Health Organization; Peter Beyer, World Health Organization; Nicolas Clark, World Health Organization; Neelam Dhingra-Kumar, World Health Organization; Martin Donoghoe, World Health Organization; Philippa Easterbrook, World Health Organization; Sergey Eremin, World Health Organization; Marta Gacic-Dobo, World Health Organization; Jesus Maria Garcia Calleja, World Health Organization; Massimo Ghidinelli, World Health Organization; Charles Gore, World Hepatitis Alliance; Angelos Hatzakis, Hepatitis B and C Public Policy Association; Lisa Hedman, World Health Organization; Ana Maria Henao Restrepo, World Health Organization; Greet Hendrickx, University of Antwerp; Karen Hennessey, World Health Organization; Sowmya Kadandale, World Health Organization; Karyn Kaplan, Treatment Action Group (TAG); Achim Kautz, European Liver Patients Association (ELPA); Selma Khamassi, World Health Organization; Tinne Lernout, Viral Hepatitis Prevention Board; Ying-Ru Jacqueline Lo, World Health Organization; Niklas Luhmann, Médecins du Monde; Frank Lule, World Health Organization; Mamunur Malik, World Health Organization; Ana Maria Padilla Marroquin, World Health Organization; Isabelle Meyer-Andrieux, Médecins sans Frontières; Antons Mozalevski, World Health Organization; Carmem Lucia Pessoa da Silva, World Health Organization; Vason Pinyowiat, World Health Organization; Tatjana Reic, European Liver Patients Association (ELPA); Gabriele Riedner, World Health Organization; Anita Sands, World Health Organization; Gerard Schmets, World Health Organization; Andreas Ullrich, World Health Organization; Annette Verster, World Health Organization; Jack Wallace, Coalition for the Eradication of Viral Hepatitis in Asia-Pacific (CEVHAP); Nick Walsh, World Health Organization; Eric Wiesen, World Health Organization; Stefan Wiktor, World Health Organization; Junping Yu, World Health Organization.

This work was coordinated and the document edited by Hande Harmanci, World Health Organization. The early drafts were written by Joe Schofield and Sarah Hess. Technical editing was done by Bandana Malhotra, New Delhi, India.

Global Hepatitis Programme, World Health Organization

ABBREVIATIONS AND ACRONYMS

| | |
|----------------|--|
| CLD | chronic liver disease |
| EIA | enzyme immunoassay |
| HAV | hepatitis A virus |
| HBeAg | hepatitis B e antigen |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HDV | hepatitis D virus |
| HEV | hepatitis E virus |
| ICT | information and communication technology |
| IEC | information, education and communication |
| Ig | immunoglobulin |
| IHP+ | International Health Partnership+ |
| IPC | infection prevention and control |
| JANS | Joint Assessment of National Strategies |
| M&E | monitoring and evaluation |
| MoH | ministry of health |
| MSM | men who have sex with men |
| NAT | nucleic acid testing |
| NGO | nongovernmental organization |
| NHA | national health accounts |
| NSP | needle and syringe programme |
| OST | opioid substitution therapy |
| PWID | people who inject drugs |
| STAG | Strategic and Technical Advisory Group |
| STI | sexually transmitted infection |
| SWOT | strengths, weaknesses, opportunities and threats |
| TB | tuberculosis |
| UHC | universal health coverage |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27321

